Literature DB >> 10698554

Kinase receptor activation (KIRA): a rapid and accurate alternative to end-point bioassays.

M D Sadick1, A Intintoli, V Quarmby, A McCoy, E Canova-Davis, V Ling.   

Abstract

We have developed a novel strategy for a rapid bioassay that is accurate, precise, sensitive, and high capacity. It is capable of quantifying ligand bioactivity by measuring ligand-induced receptor tyrosine kinase activation in terms of receptor phosphorylation. The assay, termed a 'kinase receptor activation' or KIRA, utilizes two separate microtiter plates, one for ligand stimulation of intact cells, and the other for receptor capture and phosphotyrosine ELISA. The assay makes use of either endogenously expressed receptors or stably transfected receptors with a polypeptide flag. KIRA assays for the ligands IGF-I and NGF were compared to their corresponding endpoint bioassays (3T3 cell proliferation for IGF-I and PC12 cell survival for NGF). The KIRA assays showed excellent correlation with the more classical endpoint bioassays. Further, they were highly reproducible, minimizing the requirement for repeat assays. The KIRA assay format has great potential as a rapid, accurate and precise bioassay, both for potency determination as well as stability-indicating analyses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10698554     DOI: 10.1016/s0731-7085(98)00144-7

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

Review 1.  Progress in the use of biological assays during the development of biotechnology products.

Authors:  A R Mire-Sluis
Journal:  Pharm Res       Date:  2001-09       Impact factor: 4.200

2.  Investigating the Role of Artemin Glycosylation.

Authors:  Qiu Danwen; Christian Code; Chao Quan; Bang-Jin Gong; Joseph Arndt; Blake Pepinsky; Kasper D Rand; Damian Houde
Journal:  Pharm Res       Date:  2016-02-23       Impact factor: 4.200

Review 3.  Targeting the IGF-Axis for Cancer Therapy: Development and Validation of an IGF-Trap as a Potential Drug.

Authors:  Yinhsuan Michely Chen; Shu Qi; Stephanie Perrino; Masakazu Hashimoto; Pnina Brodt
Journal:  Cells       Date:  2020-04-29       Impact factor: 6.600

4.  Modeling the Insulin-Like Growth Factor System in Articular Cartilage.

Authors:  Lihai Zhang; David W Smith; Bruce S Gardiner; Alan J Grodzinsky
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

Review 5.  IGF-I assays: current assay methodologies and their limitations.

Authors:  David R Clemmons
Journal:  Pituitary       Date:  2007       Impact factor: 3.599

6.  Potency of Full-Length MGF to Induce Maximal Activation of the IGF-I R Is Similar to Recombinant Human IGF-I at High Equimolar Concentrations.

Authors:  Joseph A M J L Janssen; Leo J Hofland; Christian J Strasburger; Elisabeth S R van den Dungen; Mario Thevis
Journal:  PLoS One       Date:  2016-03-18       Impact factor: 3.240

7.  Growth Hormone and Insulin-like Growth Factor-I Molecular Weight Isoform Responses to Resistance Exercise Are Sex-Dependent.

Authors:  Joseph R Pierce; Brian J Martin; Kevin R Rarick; Joseph A Alemany; Jeffery S Staab; William J Kraemer; Wesley C Hymer; Bradley C Nindl
Journal:  Front Endocrinol (Lausanne)       Date:  2020-08-21       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.